Health care reform: How personalized medicine could help bundling of care for liver diseases
Lopa Mishra – 27 January 2011
Ribavirin enhances interferon‐stimulated gene transcription by activation of the interferon‐stimulated response element
Qiuwei Pan, Hugo W. Tilanus, Harry L.A. Janssen, Luc J. W. van der Laan – 27 January 2011
Of mice and men: The nonrandom genomic instability in hepatocarcinogenesis
Diego F. Calvisi – 27 January 2011
A woman with improving cholestasis but hepatitis aggravating
Hao‐Chun Yu, Yung‐Hsiang Hsu, Chi‐Tan Hu – 27 January 2011
Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma
Seung‐Oe Lim, Young Min Park, Hyeon Seop Kim, Xiaoyuan Quan, Jeong Eun Yoo, Young Nyun Park, Gi Hong Choi, Guhung Jung – 27 January 2011 – The tumor suppressor p53 is a key prognostic factor in hepatocellular carcinoma (HCC), yet only 35% of grade III tumors exhibit mutation of p53. Several other pathways have been implicated in HCC and, among these, the role of the Notch1/Snail pathway remains unclear. Therefore, we investigated the expression of p53, Notch1, and Snail proteins in HCC with regard to both clinical grade and p53 mutational status.
Fibrinogen‐γ proteolysis and solubility dynamics during apoptotic mouse liver injury: Heparin prevents and treats liver damage
Sujith V. W. Weerasinghe, David S. Moons, Peter J. Altshuler, Yatrik M. Shah, M. Bishr Omary – 27 January 2011 – Fas ligand (FasL)‐mediated hepatocyte apoptosis occurs in the context of acute liver injury that can be accompanied by intravascular coagulation (IC). We tested the hypothesis that analysis of selected protein fractions from livers undergoing apoptosis will shed light on mechanisms that are involved in liver injury that might be amenable to intervention.
Erratum: Primary hepatocyte culture supports hepatitis C virus replication: A model for infection‐associated hepatocarcinogenesis
Krishna Banaudha, Jan M. Orenstein, Tamara Korolnek, Georges C. St. Laurent, Takaji Wakita, Ajit Kumar – 27 January 2011
Modeling and therapy of human liver diseases using induced pluripotent stem cells: How far have we come?
Alejandro Soto‐Gutierrez, Edgar Tafaleng, Victoria Kelly, Jayanta Roy‐Chowdhury, Ira J. Fox – 27 January 2011
Is this really the end of beta‐blockers in patients with cirrhosis and refractory ascites?
Thierry Thevenot, Jean‐Paul Cervoni, Elisabeth Monnet, Frances Sheppard, Vincent Di Martino – 27 January 2011
Survival of the fittest: Selection of hepatitis C virus variants during liver graft reinfection
Ingmar Mederacke, Thomas von Hahn – 27 January 2011